Does jardiance lower blood pressure
Pro Research Analysisby 
Searched over 200M research papers
The Impact of Jardiance (Empagliflozin) on Blood Pressure
Introduction to Jardiance and Its Mechanism of Action
Jardiance, known generically as empagliflozin, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used primarily for the treatment of type 2 diabetes mellitus (T2DM). By inhibiting the reabsorption of glucose in the renal tubules, empagliflozin promotes glucosuria, which helps in lowering blood glucose levels independently of insulin Scheen2015Frampton2018Scott2014.
Blood Pressure Reduction with Jardiance
Mechanism of Blood Pressure Reduction
Empagliflozin's ability to lower blood pressure is primarily attributed to its osmotic diuretic effect. By promoting the excretion of glucose and sodium through urine, it reduces plasma volume, which in turn lowers arterial blood pressure Scheen2015Frampton2018. This diuretic effect is beneficial in managing both systolic and diastolic blood pressure.
Clinical Evidence of Blood Pressure Reduction
Multiple clinical trials have demonstrated the efficacy of empagliflozin in reducing blood pressure. In controlled trials lasting from 24 to 104 weeks, empagliflozin was shown to reduce systolic blood pressure by approximately 4 mm Hg and diastolic blood pressure by about 2 mm Hg . These findings are consistent across various studies, indicating a modest but significant reduction in blood pressure among patients treated with empagliflozin Frampton2018Scott2014.
Additional Benefits and Considerations
Cardiovascular and Renal Benefits
Beyond its antihyperglycemic and blood pressure-lowering effects, empagliflozin has shown cardioprotective and renoprotective properties. The EMPA-REG OUTCOME trial highlighted its benefits in reducing cardiovascular events in patients with established cardiovascular disease, independent of its glucose-lowering effects . This makes empagliflozin a valuable option for patients with T2DM who are at high cardiovascular risk.
Safety and Tolerability
Empagliflozin is generally well tolerated, with most adverse events being mild to moderate. However, it is important to monitor for potential side effects such as mycotic genital infections and, in rare cases, mild urinary tract infections Scheen2015Frampton2018. The risk of hypotension and volume depletion is low but should be carefully monitored in more vulnerable patients .
Conclusion
Empagliflozin (Jardiance) not only effectively manages blood glucose levels in patients with type 2 diabetes but also offers additional benefits, including modest reductions in blood pressure. Its osmotic diuretic effect plays a crucial role in lowering both systolic and diastolic blood pressure, making it a valuable therapeutic option for patients with T2DM, especially those with concurrent cardiovascular risks.
Sources and full results
Most relevant research papers on this topic
[EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Empagliflozin effectively treats type 2 diabetes by reducing blood sugar levels and weight, while also promoting weight reduction and lowering arterial blood pressure.
Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.
Ultrasound renal denervation (uRDN) is a safe and effective treatment for reducing blood pressure and improving blood pressure control up to 36 months, with no new long-term safety concerns identified.
DOI
[Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type].
Empagliflozin effectively reduces blood sugar levels in type 2 diabetes patients, potentially reducing body mass loss and promoting weight loss.
Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial.
Patients initially assigned to sham treatment who remained uncontrolled had significant reductions in blood pressure after crossover to ultrasound renal denervation.
DOI